

1 **Identification and functional analysis of a novel mitochondria-localized 2-Cys**
2 **peroxiredoxin BbTPx-2 from *Babesia bovis***

3

4 **Authors**

5 Tatsunori Masatani ^{a*}, Masahito Asada ^b, Hassan Hakimi ^b, Kei Hayashi ^{c, d}, Junya
6 Yamagishi ^e, Shin-ichiro Kawazu ^h, Xuenan Xuan ^{h*}

7

8 **Addresses**

9 ^a Transboundary Animal Diseases Research Center, Joint Faculty of Veterinary
10 Medicine, Kagoshima University, 1-21-24 Korimoto, Kagoshima 890-0065, Japan

11 ^b Department of Protozoology, Institute of Tropical Medicine (NEKKEN), Nagasaki
12 University, 1-12-4 Sakamoto, Nagasaki 852-8523, Japan.

13 ^c Laboratory of Veterinary Parasitology, Faculty of Agriculture, Iwate University, 3-18-8
14 Ueda, Morioka 020-8550, Japan

15 ^d Department of Pathogenic Veterinary Science, United Graduate School of Veterinary
16 Science, Gifu University, 1-1 Yanagido, Gifu 501-1193, Japan.

17 ^e Research Center for Zoonosis Control, Hokkaido University, North 20, West 10 Kita-ku,
18 Sapporo 001-0020, Japan.

19 ^h National Research Center for Protozoan Diseases, Obihiro University of Agriculture

20 and Veterinary Medicine, Inada-cho, Obihiro, Hokkaido 080-8555, Japan

21

22 * Corresponding authors:

23 Dr. Tatsunori Masatani

24 Transboundary Animal Diseases Research Center, Joint Faculty of Veterinary Medicine,

25 Kagoshima University, 1-21-24, Korimoto, Kagoshima 890-0065, Japan

26 Tel.: +81 99 285 3611

27 Fax: +81 99 285 3589

28 E-mail: tatsunorimasatani@gmail.com; masatani@vet.kagoshima-u.ac.jp

29

30 Dr. Xuenan Xuan

31 National Research Center for Protozoan Diseases, Obihiro University of Agriculture and

32 Veterinary Medicine, Inada-cho, Obihiro, Hokkaido 080-8555, Japan

33 Tel.: +81 155 49 5648

34 Fax: +81 155 49 5643

35 E-mail: gen@obihiro.ac.jp

36

37

38 **Abstract**

39 Cysteine-based peroxidases, known as peroxiredoxins (Prx) or thioredoxin
40 peroxidases (TPx), are important antioxidant enzymes that prevent oxidative damages
41 caused by reactive oxygen species (ROS). In this study, we identified a novel 2-Cys Prx,
42 BbTPx-2 from a bovine *Babesia* parasite, *B. bovis*. BbTPx-2 cDNA encodes a
43 polypeptide of 254 amino acid residues. This protein has mitochondrial-targeting
44 peptide at N-terminal and two conserved cysteine residues of the typical 2-Cys Prx. By
45 using a thiol mixed-function oxidation assay, the antioxidant activity of *Escherichia coli*
46 expressed recombinant BbTPx-2 was revealed and this antioxidant activity was
47 comparable to that of known cytosolic 2-Cys Prx from *B. bovis*, BbTPx-1. Notably, we
48 confirmed that BbTPx-2 was expressed in the mitochondria of intra-erythrocytic *B.*
49 *bovis* merozoites. Altogether, these results suggest that the mitochondrial BbTPx-2 is an
50 antioxidative enzyme in scavenging ROS for *B. bovis*.

51

52 **Keywords**

53 Antioxidant activity / *Babesia bovis* / Mitochondria / Peroxiredoxin

54

55

56

57 **Introduction**

58 *Babesia* parasites are tick-borne intra-erythrocytic protozoa in the phylum
59 Apicomplexa. They infect a wide range of mammals, such as cattle, sheep, and
60 horses, and the majority of them are responsible for serious economic losses in the
61 livestock industry (Brown and Palmer 1999; Dewaal 2000; Schnittger et al. 2012).
62 Similar to other parasites of this phylum, such as *Plasmodium*, *Babesia* undergoes a
63 complex life cycle involving both tick and mammalian host. *Babesia* parasites initiate
64 infection in mammalian hosts by sporozoites, which are transmitted through the bites of
65 infected ticks; subsequently, the merozoites invade and replicate within the infected
66 erythrocytes, eventually leading to babesiosis (Hunfeld et al. 2008; Schnittger et al.
67 2012).

68 *Babesia bovis* is one of the most important species because of its impact on the
69 cattle industry. *B. bovis* causes bovine babesiosis with clinical features such as anemia,
70 fever, renal failure, and in severe case, cerebral babesiosis which is characterized by
71 sequestration of infected erythrocytes in the microvasculature of the brain (Homer et al.
72 2000). Cattle that have recovered from acute infection become asymptomatic carriers,
73 where the parasites persist in blood for years and recrudescence of parasitemia can
74 occur at unfixed intervals (Bock et al. 2004). Although bovine babesiosis can be
75 controlled by treatment with antiparasitic drugs, many drugs have been withdrawn from
76 the market due to safety issues or emergence of resistance (Bork et al. 2005a; Vial and

77 Gorenflot 2006). Therefore, to develop new therapeutic strategies for bovine babesiosis,
78 more detailed analysis of mechanisms essential for survival of *Babesia* parasites in the
79 host is important.

80 Since *Babesia* parasites proliferate in their mammalian hosts and the tick vectors
81 which are oxygen-rich environments, the parasite is likely to be under the toxic effects
82 of reactive oxygen species (ROS) that could cause damages to membrane lipids, nucleic
83 acid, and proteins (Robinson et al. 2010). For parasites which live in the host
84 erythrocytes, redox balance control is considered as an important biological property
85 (Müller et al. 2003; Becker et al. 2004; Bosch et al. 2015). A major source of ROS in
86 the parasite cell is heme, which is produced as a byproduct of hemoglobin digestion.
87 Moreover, these parasites have a mitochondrion with a functional electron transport
88 chain which may product ROS. To protect themselves from the damages caused by ROS,
89 malaria parasites are equipped with antioxidant enzymes, such as peroxiredoxins (Prxs)
90 (Becker et al. 2004; Kawazu et al. 2008). Prxs are known collectively as thioredoxin
91 peroxidase (TPx) and are widely distributed among both eukaryotes and prokaryotes
92 (Rhee et al. 2005). The family is classified into three groups based on the number and
93 the position of highly conserved active cysteine residues; namely, 1-Cys, typical 2-Cys
94 and atypical 2-Cys type (Vaca-Paniagua et al. 2009; Wood et al. 2003). In recent years,
95 several TPxs of malaria parasites were characterized and the structural and functional

96 properties of the enzymes have been determined as key factors for development of new
97 drugs (Kawazu et al. 2000, 2008; Richard et al. 2011; Hakimi et al. 2012, 2014, 2015;
98 Jortzik and Becker 2012). In *Plasmodium falciparum*, two typical 2-Cys Prxs, PFTPx-1
99 and PFTPx-2 are well characterized (Kawazu et al. 2008; Yano et al. 2005; Boucher et al.
100 2006). While PFTPx-1 is expressed in cytoplasm of parasite, PFTPx-2 is located in
101 mitochondria. It is suggested that the presence of PFTPx-2 in mitochondria is imperative
102 for the malaria parasites to maintain the integrity of the organelle (Boucher et al. 2006).

103 In *Babesia*, the presence of some antioxidant proteins, including superoxide
104 dismutase (SOD), catalase and glutathione peroxidase (Gpx), thioredoxin (Trx) and
105 thioredoxin reductase (TrxR) has been reported (Becuwe et al. 1992; Clarebout et al.
106 1998; Regner et al. 2014). Moreover, recently, BbTPx-1 and BgTPx-1, cytoplasmic
107 2-Cys Prxs of *B. bovis* and *B. gibsoni*, respectively, were identified and their antioxidant
108 activities were demonstrated (Tanaka et al. 2009; Masatani et al. 2014). In this study, we
109 identified a novel 2-Cys peroxiredoxin from *B. bovis*, BbTPx-2 localized to
110 mitochondria of the parasite. To our knowledge, this is the first report on the
111 mitochondrial peroxiredoxin from *Babesia* parasites.

112

113 **Materials and methods**

114 Parasites

115 The Texas strain of *B. bovis* (Hines et al. 1992) was maintained in purified bovine
116 red blood cells with GIT medium (Wako, Osaka, Japan) by a microaerophilic
117 stationary-phase culture system (Asada et al. 2012; Bork et al. 2005b).

118

119 Multiple sequence alignment analysis

120 Multiple sequence alignment of BbTPx-2 (GenBank accession no.
121 XM_001609049) with BbTPx-1, 2-Cys Prxs from *Theileria parva* (TpTPx:
122 XM_760611), *B. gibsoni* TPx-1 (BgTPx-1: AB829722), *Plasmodium falciparum* TPx-1
123 and TPx-2 (PfTPx-1: BAA97121 and PfTPx-2: XM_001350518, respectively) was
124 performed using GENETYX ver. 10 (Genetyx Co., Tokyo, Japan).

125

126 Cloning of the genes coding for TPxs of *B. bovis*

127 The RNA of *B. bovis* was prepared from cattle erythrocytes infected with *B. bovis*
128 by using TRI reagent (Sigma, St. Louis, MO, USA). Parasite cDNA was synthesized
129 from the extracted RNA by using Transcriptor First Strand cDNA Synthesis Kit (Roche
130 Diagnostics, Basel, Switzerland). The sequences of the DNA encoding *B. bovis*
131 BbTPx-1 and BbTPx-2 were amplified using the PrimeSTAR MAX enzyme (Takara
132 Bio Inc., Otsu, Japan) with the following sets of primers; forward primer (5'- CGT GCT
133 CGA GAA TTG CTG TTG GTC AAC CTG CAC-3') and reverse primer (5'- GCT

134 CGA ATT CTT ATG AGT GCT TGC TAG TAA GG -3') for BbTPx-1, and forward
135 primer (5'- CGT GCT CGA GAA ACG GTG TGT TGC GTC TAC C -3') and reverse
136 primer (5'- GCT CGA ATT CTT AAG AAA AGG TCT TGA AAA GG -3') for
137 BbTPx-2. *XhoI* and *EcoRI* sites are underlined. The PCR products were digested with
138 *XhoI* and *EcoRI*, and then ligated to pRSET-B vector (Invitrogen, Carlsbad, CA, USA).
139 The plasmids were designated as pRSET-BbTPx-1 and pRSET-BbTPx-2, respectively
140 and the nucleotide sequences were analyzed with ABI Prism 3100 Genetic Analyzer
141 (Applied Biosystems, Carlsbad, CA, USA).

142

143 Expression and purification of recombinant proteins

144 The pRSET-BbTPx-1 and pRSET-BbTPx-2 were transformed into *Escherichia*
145 *coli* strain BL21 (DE3). Recombinant BbTPx-1 and BbTPx-2 (rBbTPx-1 and rBbTPx-2,
146 respectively) were expressed as a His-tagged fusion protein in *E. coli* and purified using
147 HisTrap (GE Healthcare, Piscataway, NJ, USA). To express recombinant
148 glutathione-S-transferase (rGST), pGEX-6P1 (GE Healthcare) was transformed into *E.*
149 *coli* strain BL21 (DE3). Expressed rGST was purified using Glutathione-Sepharose 4B
150 beads (GE Healthcare). After dialysis in phosphate buffered saline (PBS), protein
151 concentrations were measured using a BCA protein assay kit (Pierce Biotechnology,
152 Rockford, IL, USA). The expressions of the recombinant proteins were confirmed by

153 performing sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE)
154 using 12% gel and standard coomassie brilliant blue staining.

155

156 Antioxidant activity assay

157 The antioxidant activity of rBbTPx-2 was evaluated by a mixed-function
158 oxidation (MFO) assay (Hakimi et al. 2012; Sauri et al. 1995; Masatani et al., 2014).

159 The reaction mixture containing 40 μ M FeCl₃, 10mM dithiothreitol (DTT), 20 mM

160 EDTA, 25mM HEPES was pre-incubated with or without the rBbTPx-1, rBbTPx-2

161 protein (200, 100, 50 and 25 μ g/ml) or rGST (200 μ g/ml) at 37 °C for 1 hour. We used

162 rGST as negative control because molecular weight (26 kDa) is similar to rBbTPx-2.

163 After the pre-incubation period, 0.5 μ g of pBluescript SK (+) plasmid DNA was added

164 and the reaction mixture was incubated for another 3 hours. Nicking of the supercoiled

165 plasmids was evaluated by 1 % agarose gel electrophoresis and ethidium bromide

166 staining.

167

168 Production of mouse anti-BbTPx-2 serum

169 For production of antisera against BbTPx-2, 10-week-old female ICR mice (Clea

170 Japan, Tokyo, Japan) were used in this study. One hundred micrograms of the

171 rBbTPx-2 was mixed with TiterMax Gold (TiterMax USA Inc., Norcross, GA, USA)

172 and subcutaneously injected into mice. On day 14 after first injection, boost
173 immunization was performed. The mouse sera were collected 20 days after the second
174 immunization. The mice were housed, fed and given clean drinking water in accordance
175 with the stipulated rules for the care and use of research animals promulgated by Obihiro
176 University of Agriculture and Veterinary Medicine, Japan (approval number: 24-118).

177

178 Western blotting

179 *B. bovis*-infected RBCs were pelleted by centrifugation, supernatants discarded,
180 and hemolyzed with 0.05% saponin. After centrifugation, the pellets were washed three
181 times by PBS and resuspended in RIPA buffer (50 mM Tris-HCl pH 8.0, 150 mM NaCl,
182 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate, and 1% NP-40). The
183 solubilized parasite pellet was mixed with equal amount of SDS-PAGE loading buffer
184 (0.1 M Tris-HCl pH 6.8, 5% SDS, 15% glycerol, 4.5% dithiothreitol, and 10%
185 2-mercaptoethanol) and heated at 100 °C for 5 min. Parasite proteins were separated by
186 SDS-PAGE (15% gel) and subsequently transferred onto a polyvinylidene difluoride
187 membrane (Amersham Hybond PVDF Blotting Membrane; GE Healthcare).
188 Membranes were blocked with a blocking solution (Blocking One; Nacalai tesque) and
189 reacted with anti-BbTPx-2 mouse serum at 1:200. Afterward the membrane was washed
190 with PBS containing 0.05% Tween 20 (PBS-T), and the

191 horseradish-peroxidase-conjugated goat anti-mouse IgG (W402B; Promega, Madison,
192 WI, USA) was reacted at 1:25,000. The signals were developed with Immobilon
193 Western Chemiluminescent HRP Substrate (Millipore, Billerica, MA, USA) and
194 detected by LAS-4000 mini luminescent imaging analyzer (Fujifilm, Tokyo, Japan).

195

196 Indirect immunofluorescent antibody test (IFAT)

197 *B. bovis*-infected RBCs (IRBCs) were incubated with 250 nM of Mitotracker Red
198 CM-H₂XRos (Invitrogen) for 20 min at 37°C and washed three times with PBS. Thin
199 smear was prepared from the IRBCs and fixed with 4% Paraformaldehyde-containing
200 0.0075% glutaraldehyde. The smear was blocked with 10% normal goat serum (Life
201 technologies, Rochester, NY, USA) in PBS, and incubated with anti-BbTPx-2 mouse
202 serum at 1:200. After washing with PBS-T, Alexa-Fluor 488 conjugated goat anti-mouse
203 IgG (Invitrogen) was used at 1:1000. Finally, nuclei were stained by Hoechst 33342 at
204 0.3 µg/ml and fluorescence was detected using a laser scanning confocal microscope
205 (Nikon A1R, Nikon, Tokyo, Japan) equipped with a × 60 objective lens (Nikon).

206

207 **Results and discussion**

208 The BbTPx-2 gene (762 bp) coded for a protein comprised to 253 amino acid
209 residues with the predicted molecular weight and theoretical isoelectric point of 28.02

210 kDa and 9.06, respectively. The multiple sequence alignment of BbTPx-2 with 2-Cys
211 Prxs from other Apicomplexan parasites revealed that two VCP motifs of the 2-Cys Prx
212 active sites (Cys 108 and Cys 227) were conserved (Fig. 1). Amino acid sequence
213 analysis by using SignalP 4.1 server (<http://www.cbs.dtu.dk/services/SignalP/>) showed
214 that the protein had no signal peptide. Notably, both PSORT II server
215 (<http://psort.hgc.jp/cgi-bin/runpsort.pl>) and TargetP 1.1 server
216 (<http://www.cbs.dtu.dk/services/TargetP/>) showed that the expected values
217 for mitochondrial localization of this protein are 60.9 % and 0.816 (the maximum values
218 are 100% in PSORT II and 1 in TargetP 1.1, respectively). Moreover, TargetP 1.1
219 predicted that this protein has mitochondrial targeting peptide at N terminal (aa 1 to 54)
220 (Fig. 1). Thus, it is expected that the mature BbTPx-2 protein comprised to 199 amino
221 acid residues with the predicted molecular weight and theoretical isoelectric point of
222 21.8 kDa and 6.29, respectively.

223 In order to demonstrate the enzymatic activity of this BbTPx-2, the coding
224 sequence of BbTPx-2 gene was amplified by RT-PCR (Fig. 2a) and cloned into the
225 prokaryotic expression vector pRSET-B. Then, recombinant rBbTPx-2 was expressed in
226 *E. coli* as a soluble protein. The purified rBbTPx-2 had an apparent molecular weight of
227 approximately 28-kDa, as determined by SDS-PAGE (Fig. 2b). Then, the antioxidant
228 activity of rBbTPx-2 was evaluated by MFO assay (Fig. 3). In this assay, the hydroxyl

229 radicals that are generated by FeCl₃ and DTT damage DNA (Sauri et al. 1995). In the
230 reaction mixture containing both FeCl₃ and DTT but not rBbTPx-1 or rBbTPx-2,
231 hydroxyl radicals nick the supercoiled plasmid DNA, thereby apparent size of the
232 plasmid was increased (Fig. 3, lane 4). However, the presence of 200 and 100 µg/ml of
233 rBbTPx-2 in the reaction mixtures prevented nicking of the supercoiled plasmid DNA
234 (Fig. 3, lanes 11 and 12) and this antioxidant activity was comparable to that of
235 rBbTPx-1 (Fig. 3, lanes 7 and 8). These results strongly suggested that BbTPx-2 has
236 antioxidant activity similar toBbTPx-1 and acts as an antioxidant enzyme catalyzing
237 hydrogen peroxide in the antioxidant system of *B. bovis*.

238 Next, we produced an antiserum against rBbTPx-2 and analyzed the expression of
239 BbTPx-2 in *B. bovis* by Western blotting and IFAT (Fig. 4). Western blot analysis
240 showed that an antiserum against rBbTPx-2 bound to a protein of the expected
241 monomeric size of about 24-kDa in extracts of *B. bovis*-infected RBCs (Fig. 4a). This
242 band, which is smaller than 28 kDa from rBbTPx-2, suggests that most BbTPx-2
243 proteins in the parasite are expressed as a mature protein with cleaved mitochondrial
244 targeting signal. The lack of any additional bands in the Western blotting experiment
245 shows the specificity of the mouse polyclonal antiserum in detecting only the target
246 protein. Collectively, this data indicates that BbTPx-2 is expressed in *B. bovis*
247 merozoites. IFAT with antiserum against rBbTPx-2 (Fig. 4b) revealed that the dots-like

248 strong fluorescence with some diffused signal in the cytoplasm of the parasites. Notably,
249 co-localization of anti-BbTPx-2 signal (green) with Mitotracker (red) indicates that
250 most of BbTPx-2 was present in mitochondria of parasites as predicted by bioinformatics
251 analysis (Fig. 4b, Merged). Taken together, our results indicate that BbTPx-2 is
252 expressed in mitochondria during the asexual stage of *B. bovis*.

253 In conclusion, we have characterized a novel functional antioxidant typical 2-Cys
254 Prx, BbTPx-2 in *B. bovis* mitochondria. Because BbTPx-2 has the antioxidant activity,
255 we believe that the BbTPx-2 plays a vital role in the reduction of ROS produced in
256 mitochondria. On the other hand, *Babesia* parasites have other antioxidant proteins,
257 including SOD, catalase, Gpx and another 2-Cys Prx, BbTPx-1 (Becuwe et al. 1992;
258 Clarebout et al. 1998; Tanaka et al. 2009). Thus, it would be interesting to elucidate
259 relation between BbTPx-2 and these antioxidant proteins. Further experiments
260 dissecting the precise roles of the BbTPx-2 using knock-out system (Asada et al. 2012,
261 2015) will help to gain a better understanding of the antioxidant system of the parasite.
262 Recently it was reported that the expression of a mitochondrial peroxiredoxin in
263 *Leishmania donovani* protects the parasites against hydrogen peroxide-induced cell
264 death (Harder et al. 2006). Moreover, Teixeira et al. (2015) revealed that mitochondrial
265 Prx of *L. infantum* functions as a chaperon reservoir which allows parasites to deal with
266 protein unfolding conditions during the transition from insect-stage to mammalian-stage.

267 Thus, it is interesting to reveal other functions of mitochondrial BbTPx-2 in future studies.
268 Our data may provide important information on BbTPx-2 that can be used as a base for
269 future studies to investigate its precise role in the parasite and its potential as a drug
270 target against bovine babesiosis.

271

272 **Acknowledgements**

273 This work was partially supported by a grant from the Global COE program (Grant No.
274 J02), Sasakawa Scientific Research Grant from The Japan Science Society (Grant No.
275 24-404) and Grant-in-Aid for Scientific Research (KAKENHI) from the Ministry of
276 Education, Culture, Sports, Science and Technology (MEXT), Japan (Grant Nos.
277 25850199 and 15K18783).

278

279

280 **References**

281 Asada M, Tanaka M, Goto Y, Yokoyama N, Inoue N, Kawazu S (2012) Stable
282 expression of green fluorescent protein and targeted disruption of thioredoxin
283 peroxidase-1 gene in *Babesia bovis* with the WR99210/dhfr selection system. Mol
284 Biochem Parasitol 181: 162-170.

285

286 Asada M, Yahata K, Hakimi H, Yokoyama N, Igarashi I, Kaneko O, Suarez CE, Kawazu
287 S (2015) Transfection of *Babesia bovis* by double selection with WR99210 and
288 blasticidin-S and its application for functional analysis of thioredoxin peroxidase-1.
289 PLoS One 10: e0125993.

290

291 Becker K, Tilley L, Vennerstrom JL, Roberts D, Rogerson S, Ginsburg H (2004)
292 Oxidative stress in malaria parasite-infected erythrocytes: host-parasite interactions. Int
293 J Parasitol 34: 163-189.

294

295 Becuwe P, Slomianny C, Valentin A, Schrevel J, Camus D, Dive D (1992) Endogenous
296 superoxide dismutase activity in two *Babesia* species. Parasitology 105, 177-182.

297

298 Bock R, Jackson L, de Vos A, Jorgensen W (2004) Babesiosis of cattle. Parasitology
299 129: S247-269.

300

301 Bork S, Yokoyama N, Igarashi I (2005a) Recent advances in the chemotherapy of
302 babesiosis by Asian scientists: toxoplasmosis and babesiosis in Asia. Asian Parasitol 4:
303 233-242.

304

305 Bork S, Okamura M, Matsuo T, Kumar S, Yokoyama N, Igarashi I (2005b) Host serum
306 modifies the drug susceptibility of *Babesia bovis in vitro*. Parasitology 130: 489-492.
307

308 Bosch SS, Kronenberger T, Meissner KA, Zimbres FM, Stegehake D, Izui NM, Schettert
309 I, Liebau E, Wrenger C (2015) Oxidative stress control by apicomplexan parasites.
310 Biomed Res Int 2015: 351289.
311

312 Boucher IW, McMillan PJ, Gabrielsen M, Akerman SE, Brannigan JA, Schnick C,
313 Brzozowski AM, Wilkinson AJ, Muller S (2006) Structural and biochemical
314 characterization of a mitochondrial peroxiredoxin from *Plasmodium falciparum*. Mol
315 Microbiol 61: 948-959.
316

317 Brown WC, Palmer GH (1999) Designing blood-stage vaccines against *Babesia bovis*
318 and *B. bigemina*. Parasitol Today 15: 275-281.
319

320 Clarebout G, Gamain B, Precigout E, Gorenflot A, Slomianny C, Camus D, Dive D
321 (1998) *Babesia hylomysci* and *B. divergens*: presence of antioxidant enzymes destroying
322 hydrogen peroxide. Parasitol Res 84: 75-77.
323

324 Dewaal DT (2000) Global important of piroplasmosis. J Protozool Res 10: 106-127.
325
326 Hakimi H, Asada M, Angeles JM, Inoue N, Kawazu S (2012) Cloning and
327 characterization of *Plasmodium vivax* thioredoxin peroxidase-1. Parasitol Res 111:
328 525-529.
329
330 Hakimi H, Sukanuma K, Usui M, Masuda-Sukanuma H, Angeles JM, Asada M, Kawai S,
331 Inoue N, Kawazu S (2014) *Plasmodium knowlesi* thioredoxin peroxidase 1 binds to
332 nucleic acids and has RNA chaperone activity. Parasitol Res 113: 3957-3962.
333
334 Hakimi H, Goto Y, Sukanuma K, Angeles JM, Kawai S, Inoue N, Kawazu S (2015)
335 Development of monoclonal antibodies against *Plasmodium falciparum* thioredoxin
336 peroxidase 1 and its possible application for malaria diagnosis. Exp Parasitol 154: 62-66.
337
338 Harder S, Bente M, Isermann K, Bruchhaus I (2006) Expression of mitochondrial
339 peroxiredoxin prevents programmed cell death in *Leishmania donovani*. Eucaryot Cell
340 5: 861-870.
341
342 Hines SA, Palmer GH, Jasmer DP, McGuire TC, McElwain TF (1992)

343 Neutralization-sensitive merozoite surface antigens of *Babesia bovis* encoded by
344 members of a polymorphic gene family. Mol Biochem Parasitol 55: 85-94.
345
346 Homer MJ, Aguilar-Delfin I, Telford 3rd SR, Krause PJ, Persing DH (2000) Babesiosis.
347 Clin Microbiol Rev 13: 451-469.
348
349 Hunfeld KP, Hildebrandt A, Gray JS (2008) Babesiosis: recent insights into an ancient
350 disease. Int J Parasitol 38: 1219-1237.
351
352 Jortzik E, Becker K (2012) Thioredoxin and glutathione systems in *Plasmodium*
353 *falciparum*. Int J Med Microbiol 302: 187-194.
354
355
356 Kawazu S, Tsuji N, Hatabu T, Kawai S, Matsumoto Y, Kano S (2000) Molecular
357 cloning and characterization of a peroxiredoxin from the human malaria parasite
358 *Plasmodium falciparum*. Mol Biochem Parasitol 109: 165-169.
359
360 Kawazu S, Komaki-Yasuda K, Oku H, Kano S (2008) Peroxiredoxins in malaria
361 parasites: parasitologic aspects. Parasitol Int 57: 1-7.

362

363 Masatani T, Asada M, Ichikawa-Seki M, Usui M, Terkawi MA, Hayashi K, Kawazu S,
364 Xuan X (2014) Cloning and characterization of a 2-Cys peroxiredoxin from *Babesia*
365 *gibsoni*. J Vet Med Sci 76: 139-143.

366

367 Müller S, Walter RD, Krauth-Siegel RL (2003) Thiol-based redox metabolism of
368 protozoan parasite. Trends Parasitol 19: 320-328.

369

370 Regner EL, Thompson CS, Iglesias AA, Guerrero SA, Arias DG (2014) Biochemical
371 characterization of thioredoxin reductase from *Babesia bovis*. Biochemie 99: 44-53.

372

373 Rhee SG, Chae HZ, Kim K (2005) Peroxiredoxins: a historical overview and
374 speculative preview of novel mechanisms and emerging concepts in cell signaling. Free
375 Radic Biol Med 38: 1543-1552.

376

377 Richard D, Bartfai R, Volz J, Ralph SA, Muller S, Stunnenberg HG, Cowman AF (2011)
378 A genome-wide chromatin-associated nuclear peroxiredoxin from the malaria parasite
379 *Plasmodium falciparum*. J Biol Chem 86: 11746-11755.

380

381 Robinson MW, Hutchinson AT, Dalton JP, Donnelly S (2010) Peroxiredoxin: a central
382 player in immune modulation. *Parasite Immunol* 32: 305-313.

383

384 Sauri H, Butterfield L, Kim A, Shau H (1995) Antioxidant function of recombinant
385 natural killer enhancing factor. *Biochem Biophys Res Commun* 208: 964-969.

386

387 Schnittger L, Rodriguez AE, Florin-Christensen M, Morrison DA (2012) *Babesia*: A
388 world emerging. *Infect Genet Evol* 12: 1788-1809.

389

390 Tanaka M, Sakurai T, Yokoyama N, Inoue N, Kawazu S (2009) Cloning and
391 characterization of peroxiredoxin in *Babesia bovis*. *Parasitol Res* 105: 1473-1477.

392

393 Teixeira F, Castro H, Cruz T, Tse E, Koldewey P, Southworth DR, Tomás AM, Jakob U
394 (2015) Mitochondrial peroxiredoxin functions as crucial chaperone reservoir in
395 *Leishmania infantum*. *Proc Natl Acad Sci U S A* 112: E616-624.

396

397 Vaca-Paniagua F, Parra-Unda R, Landa A (2009) Characterization of one typical 2-Cys
398 peroxiredoxin gene of *Taenia solium* and *Taenia crassiceps*. *Parasitol Res* 105: 781-787.

399

400 Vial HJ, Gorenflot A (2006) Chemotherapy against babesiosis. *Vet Parasitol* 138:
401 147-160

402

403 Wood ZA, Schroder E, Robin-Harris J, Poole LB (2003) Structure, mechanism and
404 regulation of peroxiredoxins. *Trends Biochem Sci* 28: 32-40.

405

406 Yano K, Komaki-Yasuda K, Kobayashi T, Takemae H, Kita K, Kano S, Kawazu S
407 (2005) Expression of mRNAs and proteins for peroxiredoxins in *Plasmodium*
408 *falciparum* erythrocytic stage. *Parasitol Int* 54: 35-41.

409

410

411 **Figure captions**

412 **Fig. 1**

413 Multiple sequence alignment of the deduced amino acid sequences of BbTPx-2 with the
414 sequences of other 2-Cys Prxs from *T. parva* (TpTPx), *B. bovis* (BbTPx-1), *B. gibsoni*
415 (BgTPx-1), and *P. falciparum* (PfTPx-1 and PfTPx-2). Black boxes with white letters
416 show identical residues among all the sequences, and gray boxes with black letters show
417 common residues in many of the sequences. The dashes indicate gaps introduced
418 between the sequences. Red box shows predicted mitochondrial targeting peptide of

419 BbTPx-2.

420

421 **Fig. 2**

422 Amplification of BbTPx-2 gene and expression of BbTPx-2 in *E. coli*. (a) Agarose gel
423 electrophoresis images of the RT-PCR-amplified BbTPx-2 gene (765 bp). M, 100 bp
424 DNA ladder marker. (b) SDS-PAGE images of recombinant BbTPx-2 (rBbTPx-2). M,
425 protein marker.

426

427 **Fig. 3**

428 MFO assay to evaluate rBbTPx-2 antioxidant activity. Nicking of the supercoiled
429 plasmids by the MFO was evaluated on 1.0% agarose gels stained with ethidium bromide.
430 The nicked form (NF) and supercoiled form (SF) of the plasmid are indicated on the right.
431 M, 100 bp DNA ladder marker. Lane 1, pBluescript plasmid DNA only; lane 2,
432 pBluescript plasmid DNA and FeCl₃; lane 3, pBluescript plasmid DNA and DTT; lane 4,
433 pBluescript plasmid DNA, FeCl₃ and DTT; lanes 5–8, pBluescript plasmid DNA, FeCl₃,
434 DTT, and 25, 50, 100 and 200 µg/ml of rBbTPx-1 protein, respectively; lanes 9–12,
435 pBluescript plasmid DNA, FeCl₃, DTT, and 25, 50, 100 and 200 µg/ml of rBbTPx-2
436 protein, respectively; lane 13, pBluescript plasmid DNA, FeCl₃, DTT, and 200 µg/ml of
437 recombinant glutathione-S-transferase (rGST) from *Schistosoma japonicum* as a negative

438 control. Triangles show the increasing concentration of the recombinant protein.

439

440 **Fig. 4**

441 Molecular characterization of native BbTPx-2 in parasites. (a) Western blot analysis of

442 native BbTPx-2. The positions of molecular mass standards are indicated on the left. (b)

443 Indirect immunofluorescence microscopy to determine the cellular localization of

444 BbTPx-2 in the parasite cells. Brightfield and fluorescent images (green, BbTPx-2; red,

445 mitochondria; blue; nuclear) are merged on the one panel (Merged).

446


```

BbTPx-2 1 ---MMNGVLRRLPTASAYRAMRMLS KKTGW--LN--NDIICCFRP-----VYNQFVVRAFGTQAGSYHTNIGDLVGREFP 68
TpTPx 1 MLMKLTGISLITSFYIRNSVPLKNTFTAFHTLNRNGIKSAKTPDRISLKS VNGVNRNYSSEGLNMTVTSSLIGKLMF 80
BbTPx-1 1 -----MIAVGQPAP 9
BgTPx-1 1 -----MVVRVGPAP 10
PfTPx-1 1 -----MASYVGREAP 10
PfTPx-2 1 -----MFLKKLCRSNFFGNSRRSFLVTKKAY 27


BbTPx-2 69 DEKTSAVINGN-ITFDASAYFRDSYALLVVFYPLDFTFVCPSELLGFSARLSEFEQRGIKVVGISIDSVFSHLALQMDL 147
TpTPx 81 SFKGTALLGDD-LVQFNSSDYFKDSYGLLVFYPLDFTFVCPSELLGFSERLKEFEERHVKVLGVSVDSPFSHKAKKELDV 159
BbTPx-1 10 NFRCEAVMPDMSFKEISLSDYAGKKYVCLFFFYPLDFTFVCPTEIVAFNDAMAQFEARNVQILACSVDSKFAHVTWRNTPR 89
BgTPx-1 11 NFRCEAVMPDMSFKEISLSDYAGKKYVCLFFFYPLDFTFVCPTEIVAFNDAAQFEARNVQILACSVDSKFSHLTWRNTPR 90
PfTPx-1 11 YFKAEAVFADNTFGEVNLHDFIGKKYVLLFYPLDFTFVCPSEIIALDKALDAFKERNVELIGCSVDSKYTHLAKKTP 90
PfTPx-2 28 NETAQGLNKNMEIINVDLSSFIGQRYCCLLFYPLNYTFVCPTEIIIEFNKHIKDFENKNVELLGISVDSVYSHLAKNMP 107

BbTPx-2 148 KKGCVHGLKIPLVSDISRSISKSFGLLR-SDGFAQFASVLDRTGKVRHTAVFDLIGIRSVDETLRFVDAIKFNDESQOV 226
TpTPx 160 RQGGVSPKFPFLFSDLSREVSSSFGLLR-DEGFSHFASVLDKAGVVKHVAMYELGLGRSVDETLRLFDVAVQFAEKTGNV 238
BbTPx-1 90 DRGGIGNVMFPVLTDTITKTVCDAYEVLIPDEGVALRGLFLIDRKGIVQHLQINMLPLGRSVTEVLRIIDALQFYEKHGEV 169
BgTPx-1 91 DKAGIGKVMFPILADLTKSISTQYDVLIPDEGVALRGLFLIDRKGMLQHQVMMNLPIGRAWNEVLRVVDALQFYEKAGEL 170
PfTPx-1 91 TKGIGNIQHTLISDITKISRSYNVLF-GDSVSLRAFVLDKQGVVQHLVMMNLAIGRSVEEVLRIIDAVQHHEQHGCV 169
PfTPx-2 108 EKGIGNVEFTLVSDINKDISKNYVLY-DNSFALRGLFLIDRKGCVRHQTVNDLPIGRNWQEVLRITIDSIIHVDTSGEV 186


BbTPx-2 227 CPWNWQKGGAGMSQTSSSTGDYLFKTF-- 254
TpTPx 239 CPWNWQKGDQAMKPDQSQVKOYLSNRFN-- 266
BbTPx-1 170 CPANWKAGDKGMAATTEGVIAHLTSKHS-- 197
BgTPx-1 171 CPANWKAGDKGMAATSEAVVAHLTTKLS-- 198
PfTPx-1 170 CPANWKKGKVMKPSSEEGVSEYLSK---- 195
PfTPx-2 187 CPINWKKGQAKFPTTESLIDYMNWANKNV 216

```


a




b



Masatani et al.
Fig. 2



Masatani et al.
Fig. 3



Masatani et al.
Fig. 4